KSQ Therapeutics utilizes its CRISPRomics® platform to identify and target the genome's most promising therapeutic candidates for curing human diseases. The company is advancing CRISPR/Cas9-engineered Tumor Infiltrating Lymphocytes (eTIL®) programs to develop effective treatments for cancer.
Funding
$294M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often lack specificity, leading to off-target effects and limited efficacy, particularly in solid tumors with complex microenvironments. Engineering effective tumor-infiltrating lymphocytes (TILs) to target and eradicate cancer cells remains a significant challenge.
Solution
KSQ Therapeutics employs its CRISPRomics® platform to pinpoint and validate optimal therapeutic targets within the genome for cancer treatment. This platform facilitates the development of CRISPR/Cas9-engineered Tumor Infiltrating Lymphocytes (eTIL®) designed to selectively target and destroy tumor cells. By precisely editing TILs, KSQ aims to enhance their ability to infiltrate tumors, recognize cancer-specific antigens, and overcome immunosuppressive mechanisms within the tumor microenvironment. The eTIL® programs are designed to improve the efficacy and safety of adoptive cell therapies for solid tumors.
Target Audience
The primary target audience includes patients with solid tumors who are refractory to standard treatments, as well as oncologists and researchers seeking innovative approaches to cancer immunotherapy.
Features
- CRISPRomics® platform for systematic, genome-scale target discovery and validation
- CRISPR/Cas9-based engineering of TILs to enhance tumor-killing capabilities
- eTIL® programs designed to improve tumor infiltration and persistence
- Focus on developing treatments for solid tumors with unmet medical needs